Problem: Plasminogen activator inhibitor-1 (PAI-1) is elevated in women with polycystic ovary syndrome (PCOS), but the regulation in granulosa cells (GCs) is unclear.
the activation of plasminogen to plasmin within the follicular fluid, and ultimately results in controlled proteolytic breakdown of the follicular wall. 5, 6 Levels of t-PA peak within the granulosa cells (GCs) of the preovulatory follicle just prior to ovulation, while PAI-1 is at low level, thus leading to selective rupture of the follicle. 4, 5, 7 Interestingly, Devin et al. reported that transgenic mice that constitutively express a stable form of human PAI-1 exhibit a hypertrophied theca layer, a characteristic of human PCOS ovaries. 8 Moreover, the plasma testosterone concentration was nearly twofold greater in transgenic female mice than in wild-type mice. The group also reported that ovarian tissues from patients with PCOS exhibit intense staining for PAI-1 in GCs, whereas little PAI-1 is detected in normal ovarian tissues. 8 These data strongly support the idea that overexpressed PAI-1 is a key factor involved in the pathophysiology of PCOS. In accordance with this hypothesis, there are several reports that showed elevated levels of PAI-1 in PCOS. [9] [10] [11] [12] [13] As PAI-1 is an inhibitor for t-PA which regulates ovulation, higher amounts of PAI-1 may cause the follicle to be refractory to ovulation stimuli, one of the hallmarks of PCOS, although precise mechanisms are still unknown.
Accordingly, a better understanding of PAI-1 regulation in human
GC might result in the discovery of new strategies for the treatment of patients with PCOS. The purpose of this study was to examine the mechanisms of PAI-1 production using a newly established human non-luteinized GC line, HGrC1, 14 and seek to find new strategies to reduce PAI-1 production by GC.
| MATERIALS AND METHODS

| Reagents and materials
Fetal bovine serum (FBS), DMEM, antibiotics (mixture of penicillin, streptomycin, and amphotericin B), and simvastatin were purchased from Sigma (St. Louis, MO, USA). Recombinant human TNF-α and TGF-β were purchased from R&D Systems (Minneapolis, MN, USA).
| Culture of HGrC1 cells
HGrC1 cells were cultured with TGF-β (0-300 ng/mL) or TNF-α (0-300 ng/mL) for up to 48 hours. In some experiments, MAPK in- To obtain PFMCs, the peritoneal fluid (PF) obtained at surgery was used. 16 Briefly, the PFs from benign ovarian tumor patients were 
| Reverse transcription and quantitative real-time PCR Analysis
Total RNA was extracted from HGrC1, using the ISOGEN II (Nippon Gene, Tokyo, Japan). Reverse transcription was performed using
ReverTra Ace qPCR RT Master Mix with gDNA Remover (TOYOBO, Tokyo, Japan). 500 ng to one microgram of total RNA was reverse- 
| PAI-1 activity
The activity of PAI-1 in conditioned media was measured using a PAI-1 activity kit (ASSAYPRO, St. Charles, MO, USA). A fixed amount of t-PA was added in excess to the supernatant of cultured HGrC1 cells, which allowed PAI-1 and t-PA to form an inactive complex. The assay measured plasminogen activation by residual t-PA in coupled assays that contain t-PA, plasminogen, and a plasmin-specific synthetic substrate. The amount of plasmin produced was quantitated using a highly specific plasmin substrate releasing a yellow para-nitroaniline (pNA) chromophore. The absorbance of the pNA at 405 nm was inversely proportional to the PAI-1 enzymatic activity. The intra-and interassay coefficients of variation were 4.7% and 7.0%, respectively, in the assays.
| Immunohistochemistry
A total of six ovarian sections were used in the study. Normal ovaries 
| Western blotting
After pre-treatment of control or simvastatin (5 μmol/L), HGrC1 cells
were stimulated with TGF-β (1 ng/mL) and/or TNF-α (5 ng/mL) for Immune complexes were visualized by the use of WesternSu re ECL Substrate (LI-COR).
| Statistical analysis
All experiments were repeated at least three times, and all measurements were taken in at least duplicate. Data are presented as mean±SEM. Non-normally distributed data were analyzed by nonparametric tests (Kruskal-Wallis one-way analysis of variance) using JMP software (SAS Institute Inc., Cary, NC, USA). A P-value of <.05
was considered statistically significant.
| RESULTS
| Localization of human PAI-1 antigen within human ovaries
We confirmed the location of PAI-1 accumulation in human ovary specimens. As reported before, 8 in normal ovaries, PAI-1 was scantly detected in the healthy follicles ( Figure 1A,D) , while PAI-1 accumulation was evident within polycystic ovary specimens and localized lining cystic structures ( Figure 1B ). PAI-1 expression was observed in cytoplasm of granulosa cells mainly and some of theca cells ( Figure 1C) . In normal ovary, healthy follicles with multilayered GC (Figure 1D, lower) exhibited very low expression of PAI-1 in GCs, while GCs of unhealthy follicles that were thin-layered and partially detached from membrane exhibited distinct PAI-1 expression ( Figure 1D , upper). The abovementioned features of PAI-1 expression pattern were observed in all ovarian sections, three normal and three PCOS ovaries.
| TGF-β and TNF-α induced PAI-1 mRNA expression and PAI-1 activity in HGrC1 cells
In a pilot study, various stimuli including antimullerian hormone (AMH, 100 ng/mL), androstenedione (5 nM), luteinizing hormone/human chorionic gonadotropin (LH/hCG, 10 IU/mL), TGF-β and TNF-α, which could be involved in the pathophysiology of PCOS, were added to 
| Therapeutic agents that suppress PAI-1 expression
We next examined the ability of various agents to suppress PAI-1 expression in HGrC1 cells. As shown in Figure 4A , simvastatin (1 or 5 μmol/L)
did not suppress basal levels of PAI-1, but significantly suppressed TGF-β-/TNF-α-induced PAI-1 mRNA expression. Western blotting analysis
showed that TGF-β and TNF-α induced phospho-p38 in a synergistic fashion, which was inhibited with pre-treatment of simvastatin ( Figure 4B ).
We also examined the effects of insulin-sensitizing agents, such as metformin (an activator of AMPK), and the PPAR γ agonists, pioglitazone and rosiglitazone. In HGrC1 cells, all of insulin-sensitizing agents failed to suppress basal PAI-1 mRNA expression levels and also had no effect on the mRNA expression induced by simultaneous addition of TGF-β and TNF-α (data not shown).
As TNF-α and TGF-β are reported to be produced in macrophages of patients with PCOS, 17, 18 we investigated the expression of TGF-β and TNF-α in PFMCs. Insulin-sensitizing drugs failed to suppress basal levels of TGF-β and TNF-α, but significantly suppressed LPS-induced TGF-β and TNF-α mRNA expression in PFMCs ( Figure 5A ,B).
| DISCUSSION
In the present study, we found that little PAI-1 expression was observed in healthy GCs, whereas GCs of PCOS and atretic follicle Healthy follicle x400 GC layer exhibited distinct expression in vivo ( Figure 1 ). As PAI-1 is a potential factor in the etiology of PCOS, we firstly investigated the regulation of PAI-1 expression in GC using a newly established human GC line, HGrC1, derived from a small antral follicle. 14 We firstly clarified that TGF-β and TNF-α induce PAI-1 mRNA expression and activity. PCOS is described as a low-grade chronic inflammatory state mainly triggered by an increase in activated macrophage infiltration in visceral fat. 19 It has also been reported that aberrant expression of TGF-β and TNF-α is related to PCOS, and macrophages are known to primarily secrete these cytokines. 17, 18, 20, 21 In the present study, simultaneous addition of TGF-β and TNF-α had a synergistic effect on PAI-1 mRNA expression and activity, which was completely suppressed by a combination of ALK-5 and p38 MAPK inhibitors. Western blotting analysis also revealed that p38 MAPK was involved in this synergistic effect. In rat astrocytes in vitro, p38 and JNK are involved in PAI-1 up-regulation. 22 In our experiments, JNK inhibitor (SP600125) also partially suppressed PAI-1 mRNA in HGrC1 cells. 
F I G U R E 3
The effect of various inhibitors on TGF-β-and/or TNF-α -induced PAI-1 mRNA expression in a human granulosa cell line (HGrC1). A, HGrC1 cells were stimulated with TGF-β (1 ng/mL) or TNF-α (5 ng/mL) for 24 h. MAPK inhibitors, PD98059 (ERK inhibitor 25 μmol/L), SB202190 (p38MAPK inhibitor, 10 μmol/L), and SP600125 (JNK inhibitor, 10 μmol/L) and SB431542 (inhibitor of activin receptorlike kinase (ALK)-5, 10 μmol/L), were added one hour before the treatment with TGF-β or TNF-α. B, HGrC1 cells were stimulated with TGF-β (1 ng/mL) and TNF-α (5 ng/mL) for 24 h. SB202190 (p38MAPK inhibitor, 10 μmol/L) and/or SB431542 (ALK-5 inhibitor, 10 μmol/L) was added one hour before the treatment with TGF-β and TNF-α. Total RNA was extracted from the cells and subjected to real-time PCR to determine the PAI-1 mRNA levels. Data were normalized by GAPDH mRNA levels to show the relative abundance. Representative data from three different experiments were shown as the mean±SEM relative to an adjusted value of 1.0 for the mean value of the control. 
25,26
We also examined the effect of metformin, an activator of the AMPK, and the PPAR γ agonists, pioglitazone and rosiglitazone, on PAI-1 mRNA expression, because these medicines are used for the treatment of PCOS, but the actual mechanism of insulin-sensitizing agents has not been fully understood. In our current study, these agents did not regulate basal as well as TGF-β -and TNF-α -stimulated levels of PAI-1 mRNA expression in HGrC1 cells (data not shown).
However, insulin-sensitizing agents markedly suppressed LPS-induced TGF-β and TNF-α mRNA expression in PFMCs ( Figure 5 ).
As shown in Figure 6 , we hypothesize that activated macrophages might induce inflammation, leading to increased TNF-α and TGF-β synthesis, which results in the stimulation of PAI-1 expression in GCs via Each column consists of 4 samples
The effect of simvastatin on TGF-β -and/or TNF-α -induced PAI-1 expression in a human granulosa cell line (HGrC1). A, HGrC1 cells were stimulated with or without TGF-β (1 ng/mL) and TNF-α (5 ng/mL) for 3 h. Simvastatin (1 or 5 μmol/L, dissolved in DMSO) or control (DMSO) was added one hour before the treatment with TGF-β and TNF-α. Total RNA was extracted from the cells and subjected to real-time PCR to determine the PAI-1 mRNA levels. Data were normalized by GAPDH mRNA levels to show the relative abundance. Representative data from three different experiments were shown as the mean±SEM relative to an adjusted value of 1.0 for the mean value of the control. *P<.01 (vs TGF-β and TNF-α). B, After pre-treatment of control or simvastatin (5 μmol/L), HGrC1 cells were stimulated with TGF-β (1 ng/mL) and/or TNF-α (5 ng/mL) for 1 h, followed by Western blotting for p38 and phospho-p38 MAPK that metformin reduces serum PAI-1 levels in PCOS. 27 Further study is warranted to determine whether elevated PAI-1 levels in GCs would be remedied with statin and insulin-sensitizing agents in patients with PCOS, effects that were observed in serum of patients with diabetes, metabolic syndrome, or PCOS. [27] [28] [29] [30] Ultimately, the investigation into pharmacological agents that are capable of suppressing p38MAPK or Smad2/3 signaling, or directly antagonizing PAI-1, might result in discovery of potential treatments for PCOS. 8 Further study is needed to test this hypothesis.
F I G U R E 6 Schema of the hypothesis. In PCOS, activated macrophages produce TNF-α and TGF-β, 17, 18, 20, 21 which up-regulates the expression of PAI-1 in GCs. PAI-1 is a cause of polycystic ovary appearance and hypertrophied theca layer with elevated testosterone 8 . Insulin-sensitizing agents (metformin, pioglitazone, and rosiglitazone) suppress TNF-α and TGF-β expression in activated macrophages, which leads to the reduction in PAI-1 expression in GCs. Statin suppresses PAI-1 expression directly in GCs 
